HOLLY SPRINGS, N.C. – FujiFilm Diosynth Biotechnologies today announced a 10-year manufacturing supply agreement, valued at over $3 billion, with Tarrytown-based Regeneron Pharmaceuticals Inc. to provide U.S.-based production of its industry-leading biologic medicines.
A world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, FujiFilm Diosynth Biotechnologies will provide U.S.-based manufacturing for Regeneron over the life of the agreement through current and planned expansions at its new large-scale biopharmaceutical manufacturing facility in Holly Springs. That site begins operations later this year.
“This agreement with an industry-leading biologic medicines company demonstrates that FUJIFILM Diosynth Biotechnologies is trusted by our partners to deliver through our technical expertise, talented team, and operational readiness,” said Toshihisa Iida, director, corporate vice president, general manager of Life Sciences Strategy Headquarters and Bio-CDMO Division, FujiFilm Corp. of Japan.
“We are delighted to be selected as the manufacturing supply partner for Regeneron, utilizing our new state-of-the-art facility in Holly Springs, North Carolina. The Holly Springs site is part of our kojoX™ interconnected manufacturing network, which provides a first-of-its-kind modular approach with standardized equipment, processes, and procedures across our sites around the globe to help ensure supply chain security and seamless tech transfers,” said Lars Petersen, president and CEO of FujiFilm Diosynth Biotechnologies.
Regeneron executive Daniel Van Plew expects the relationship with FujiFilm to take it to the next level.
“At Regeneron, we have the privilege of making some of the best and most innovative therapeutics in the industry, and we are acutely aware of Regeneron’s impact on people’s lives as we work to help treat or even cure devastating diseases,” said Van Plew, Regeneron executive vice president and general manager of industrial operations and product supply. “We take our role seriously, and our decision to work with FUJIFILM Diosynth Biotechnologies reflects our belief that they will meet our high standards and grow with us.”
FujiFilm Corp. has made about $4 billion in the U.S. by in building world-class biopharmaceutical manufacturing sites, life sciences capabilities, and growing its technical talent, according to Iida. “Additionally, through our previously announced expansion efforts, we are pleased to share that we’ve already added 500 new positions as part of our overall goal of creating 1,400 new jobs in North Carolina by 2031,” lida said.
